Valeant Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VALEANT, and what generic alternatives to VALEANT drugs are available?
VALEANT has seventy-eight approved drugs.
There are six US patents protecting VALEANT drugs.
There are forty-four patent family members on VALEANT drugs in twelve countries and forty-one supplementary protection certificates in thirteen countries.
Summary for Valeant
| International Patents: | 44 |
| US Patents: | 6 |
| Tradenames: | 61 |
| Ingredients: | 49 |
| NDAs: | 78 |
| Patent Litigation for Valeant: | See patent lawsuits for Valeant |
Drugs and US Patents for Valeant
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Valeant Pharms Intl | COLAZAL | balsalazide disodium | CAPSULE;ORAL | 020610-001 | Jul 18, 2000 | AB | RX | Yes | Yes | 7,625,884*PED | ⤷ Subscribe | Y | ⤷ Subscribe | ||
| Valeant Bermuda | PENLAC | ciclopirox | SOLUTION;TOPICAL | 021022-001 | Dec 17, 1999 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Valeant Pharm Intl | ANDROID 5 | methyltestosterone | TABLET;BUCCAL | 087222-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Valeant Pharms | PENTOXIFYLLINE | pentoxifylline | TABLET, EXTENDED RELEASE;ORAL | 075028-001 | Jul 20, 1998 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Valeant
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Valeant Pharms North | RETIN-A | tretinoin | CREAM;TOPICAL | 017340-001 | Approved Prior to Jan 1, 1982 | 3,729,568 | ⤷ Subscribe |
| Valeant Pharms | ULTRAM ER | tramadol hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 021692-001 | Sep 8, 2005 | 6,254,887 | ⤷ Subscribe |
| Valeant Pharm Intl | PERMAX | pergolide mesylate | TABLET;ORAL | 019385-002 | Dec 30, 1988 | 4,180,582 | ⤷ Subscribe |
| Valeant Intl | RETIN-A | tretinoin | GEL;TOPICAL | 017579-002 | Approved Prior to Jan 1, 1982 | 3,729,568 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for VALEANT drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 75 mg | ➤ Subscribe | 2011-06-06 |
| ➤ Subscribe | Extended-release Tablets | 200 mg | ➤ Subscribe | 2007-03-28 |
| ➤ Subscribe | Tablets | 1.1 g | ➤ Subscribe | 2013-11-05 |
| ➤ Subscribe | Extended-release Tablets | 100 mg | ➤ Subscribe | 2007-01-08 |
| ➤ Subscribe | Extended-release Tablets | 300 mg | ➤ Subscribe | 2007-09-25 |
| ➤ Subscribe | Cream | 0.5% | ➤ Subscribe | 2011-07-29 |
International Patents for Valeant Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2011137103 | ⤷ Subscribe |
| European Patent Office | 2586427 | ⤷ Subscribe |
| Mexico | 2012012324 | ⤷ Subscribe |
| China | 105267226 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Valeant Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1458369 | C01458369/01 | Switzerland | ⤷ Subscribe | PRODUCT NAME: ADAPALENUM + BENZOYLIS PEROXIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 58460 19.05.2009 |
| 1539166 | 92323 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: LA COMBINAISON DE (A) DEXTROMETHORPHAN OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, PRECURSEURS OU DERIVES , PAR EX. HYDROBROMURE DE DEXTROMETHORPHAN ET EN PARTICULIER HYDROBROMURE DE DEXTROMETHORPHAN MONOHYDRATE; ET(B) QUINIDINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES , PRECURSEURS OU DERIVES, PAR EX. SULFATE DE QUINIDINE ET EN PARTICULIER SULFATE DE QUINIDINE DEHYDRATE; FIRST REGISTRATION: 20130624 |
| 0591275 | SPC/GB05/030 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: NITISINONE (2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE) OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/04/303/001 20050221; UK EU/1/04/303/002 20050221; UK EU/1/04/303/003 20050221 |
| 1586316 | SPC/GB11/054 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: BROMFENAC 2-AMINO-3-(4-BROMOBENZOYL)PHENYLACETIC ACID OR A PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTERED: UK EU/1/11/692/001 20110523 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
